Limited expression of TLR9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
Nadia Soledad Alegre, Cecilia Claudia Garcia, Luis Ariel Billordo, Beatriz Ameigeiras, Daniel Poncino, Javier Benavides, Luis Colombato, Alejandra Claudia Cherñavsky
Clin Mol Hepatol. 2020;26(2):216-226.   Published online 2019 Dec 5     DOI: https://doi.org/10.3350/cmh.2019.0074
Citations to this article as recorded by Crossref logo
Peripheral immune cells in NAFLD patients: A spyhole to disease progression
Shuang-Zhe Lin, Jian-Gao Fan
eBioMedicine.2022; 75: 103768.     CrossRef
TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism
Christopher R. Shepard
Frontiers in Endocrinology.2021;[Epub]     CrossRef
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome
Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo
Clinical and Molecular Hepatology.2021; 27(3): 463.     CrossRef
Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease
Anja Baumann, Anika Nier, Angélica Hernández-Arriaga, Annette Brandt, Maria J. Lorenzo Pisarello, Cheng J. Jin, Esther Pilar, Amélia Camarinha-Silva, Jörn M. Schattenberg, Ina Bergheim
Scientific Reports.2021;[Epub]     CrossRef
Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
Hyuk Soo Eun
Clinical and Molecular Hepatology.2020; 26(2): 236.     CrossRef
Limited expression of toll-like receptor 9 on T cells and its functional consequences in patients with nonalcoholic fatty liver disease
Jung Hwan Yu
Clinical and Molecular Hepatology.2020; 26(2): 240.     CrossRef
Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
Soung Won Jeong
Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef